Imugene Ltd (ASX:IMU, OTC:IUGNF) has opened the doors to a large and lucrative market for immuno-oncology by securing a Notice of Grant from the European Patent Office for its HER-Vaxx immunotherapy.
The patent covers the technology currently in development for HER-2 positive gastric cancer and protects the method of composition and method of use until 2036 in the European market.
“Attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036,” managing director Leslie Chong said.
Imugene’s HER-Vaxx is a B-cell activating immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu. It has been shown in pre-clinical studies – at Phase 1 and 2 – to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.
About Imugene
Imugene is a clinical stage immuno-oncology company developing assets that activate the immune system of cancer patients to treat and eradicate tumours.
These technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.
The company’s product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.
Imugene harnesses the expertise of a leading team of international cancer experts with extensive experience in developing new cancer therapies and aims to help transform cancer treatment and the lives of the millions of patients who need effective treatments.
Imugene is well funded and resourced to deliver on its commercial and clinical milestones, ensuring that the company and its shareholders are at the forefront of this rapidly growing global market.